Farxiga and Surgery: When to Stop and Restart the Drug

Farxiga (dapagliflozin) should generally be stopped three days before major surgery when the patient has type 2 diabetes, according to the most recent multidisciplinary consensus guidance. The concern is a rare but serious complication called euglycemic diabetic ketoacidosis, where dangerous acid levels build up in the blood even though blood sugar looks normal. But the answer is more nuanced than a blanket “stop it three days ahead,” because the recommendation depends on the type of surgery, whether you have diabetes or take Farxiga for heart failure or kidney disease alone, and how long you will be fasting.

Why Farxiga Creates a Specific Surgical Risk

Farxiga works by blocking a protein called SGLT2 in the kidneys, which normally recycles glucose back into the bloodstream. When that protein is blocked, extra glucose spills into the urine instead, lowering blood sugar through a mechanism that has nothing to do with insulin.¹ That insulin-independent action is exactly what makes the drug useful for people who do not have diabetes but do have heart failure or chronic kidney disease. It is also what makes surgery risky.

During any significant operation, your body floods itself with stress hormones like cortisol and epinephrine. Those hormones ramp up glucose production, break down fat stores, and make your tissues more resistant to insulin. For most people, this is manageable. But when Farxiga is still active, it suppresses insulin secretion from the pancreas even further. That tips the balance: less insulin relative to glucagon means the liver starts converting fatty acids into ketone bodies at an accelerated rate.² The result can be full-blown ketoacidosis, the same life-threatening acid buildup that emergency rooms associate with uncontrolled type 1 diabetes, except that blood glucose stays deceptively normal.

The Standard Hold Period and Who It Applies To

The most detailed perioperative guidance comes from a 2026 multidisciplinary consensus statement published in the British Journal of Anaesthesia by the Society for Perioperative Assessment and Quality Improvement (SPAQI). The recommendations are not one-size-fits-all. They break down by the type of surgery, whether you have type 2 diabetes, and whether you have heart failure or chronic kidney disease.

For patients with type 2 diabetes, the consensus recommends stopping Farxiga three days before surgery in the following situations:

Major noncardiac surgery: if prolonged postoperative fasting is expected
Cardiac surgery: if the patient does not also have heart failure or chronic kidney disease
Pre-surgical low-carb diets: when a very low-carbohydrate diet is required beforehand, as with some bariatric surgery preparation protocols

These recommendations reflect the fact that fasting and carbohydrate restriction are the key triggers that push someone toward ketoacidosis when Farxiga is still on board.³

For patients who take Farxiga for heart failure or kidney disease and also have diabetes, the picture is more complicated. If you have type 2 diabetes along with heart failure, the consensus actually recommends continuing Farxiga through major noncardiac and cardiac surgery, as long as you are not expected to fast from carbohydrates for more than about 12 hours before the procedure. The reasoning: stopping the drug in someone with established heart failure carries its own risks, and the ketoacidosis risk is lower when carbohydrate intake is maintained.³

When You Probably Do Not Need to Stop

Not every procedure requires holding Farxiga. For minor surgeries and procedures, the SPAQI consensus recommends continuing the drug regardless of whether the patient has diabetes. This applies to outpatient procedures, minor day surgeries, and anything where you will be eating normally within a few hours. The ketoacidosis risk is tied to prolonged fasting and surgical stress; a brief procedure under local anesthesia does not trigger the same hormonal cascade.³

Patients who do not have diabetes at all and take Farxiga purely for heart failure or chronic kidney disease also have a different risk profile. For these patients undergoing major surgery without prolonged fasting, the consensus supports continuing the drug. Only when prolonged postoperative fasting is anticipated should non-diabetic patients consider stopping, and even that recommendation is described as something to “consider” rather than a firm directive.

The Three-Day Number and Farxiga’s Half-Life

You might wonder why three days, specifically. Farxiga has a half-life of roughly 12 to 13 hours, meaning half the drug clears your system in about half a day.⁴ After three days (about five to six half-lives), the amount remaining in your body is negligible. That window gives enough clearance to substantially reduce the metabolic shift that drives ketone production.

Data from a study measuring ketone levels at the time patients arrived in the ICU or recovery room bears this out. Patients whose last Farxiga dose was at least 72 hours before surgery had meaningfully lower ketone concentrations than those who took it more recently. The difference was most pronounced in patients with the highest ketone levels: the compliant group showed substantially lower readings at the upper end of the distribution.⁵ In practical terms, following the three-day hold works. The drug is substantially gone, and your body has had time to reset the insulin-glucagon balance that surgical stress would otherwise exploit.

Emergency Surgery When You Cannot Wait Three Days

Planned surgery gives you the luxury of a clean three-day washout. Emergency surgery does not. If you need an urgent operation while Farxiga is still in your system, the drug cannot be magically cleared, and the ketoacidosis risk is real. A case series analysis found that the incidence of euglycemic ketoacidosis was roughly 1.1% in patients on SGLT2 inhibitors who underwent emergent procedures, compared with about 0.17% for nonemergent ones.⁶ That sixfold difference reflects both the inability to stop the drug ahead of time and the greater physiological stress of emergency procedures.

When emergency surgery is unavoidable, the practical approach is to manage the risk on the back end rather than the front end. Experts suggest admitting these patients postoperatively to a unit capable of monitoring for and treating euglycemic ketoacidosis, with specialist input readily available.⁷ If you are ever in an emergency room and surgery is imminent, make sure your surgical team and anesthesiologist know you take Farxiga. This is not a medication that shows up on a standard blood panel, and if the care team does not know about it, they will not be watching for the right complication.

Why Euglycemic Ketoacidosis Is So Easy to Miss

The “euglycemic” part of this complication is what makes it dangerous. In classic diabetic ketoacidosis, blood sugar is dramatically elevated, often above 250 mg/dL, and the diagnosis is obvious from routine labs. With SGLT2 inhibitor-associated ketoacidosis, blood sugar can be in a perfectly normal range because the drug is still flushing glucose out through the kidneys. The patient can look stable on paper while their blood is becoming dangerously acidic.

Symptoms often mimic common postoperative complaints: nausea, vomiting, abdominal pain, fatigue, and rapid breathing. In a recovery room full of patients feeling unwell after anesthesia, these signs are easy to attribute to the surgery itself. The only way to catch it is to actively look for it with blood gas analysis and ketone measurements, which will not happen unless someone flags that the patient was recently on an SGLT2 inhibitor.⁸ A retrospective study found that metabolic acidosis with normal glucose occurred in roughly 23% of surgical patients on SGLT2 inhibitors, compared with about 8% of controls.⁹ Most of those cases were subclinical, meaning they showed up on labs but did not progress to full ketoacidosis. Still, the gap between groups is striking and reinforces why monitoring matters.

Surgical Outcomes in Larger Datasets

A large study published in JAMA Surgery looked at postoperative ketoacidosis events across thousands of SGLT2 inhibitor users and matched controls. Using a broad biochemical definition of elevated ketones and acidosis (not just clinically diagnosed events), the study found that about 30% of SGLT2 inhibitor users met criteria for perioperative ketoacidosis, compared with roughly 28% of controls. The difference was modest overall but more pronounced in specific settings: among cardiac surgery patients, the rate was about 56% in SGLT2 inhibitor users versus 50% in controls.¹⁰

Those numbers deserve context. The study used lab-based criteria to identify events, so many of these cases were mild metabolic shifts rather than clinical emergencies. What is more telling is that patients who did develop ketoacidosis of any severity had longer hospital stays, with a median of 6 days compared to 3 days for those who did not. That practical difference in recovery time matters more to most patients than the raw incidence rate. The risk is real, but for most elective noncardiac surgeries with a proper three-day hold, the absolute increase in risk is small.

Restarting Farxiga After Surgery

The rule for restarting is straightforward: do not take Farxiga again until you are eating and drinking normally. The SPAQI consensus recommends restarting only when the patient has resumed normal oral intake.³ “Normal” here means regular meals with adequate carbohydrates, not sipping broth or tolerating a few crackers. The reason loops back to the mechanism: Farxiga shifts your metabolism toward fat burning and ketone production, and that shift is safe only when you are taking in enough carbohydrates to keep the insulin-glucagon balance in check.

For a straightforward day surgery where you eat dinner that evening, this might mean restarting the next morning. For a major abdominal operation where oral intake is restricted for several days, you might not restart for a week or longer. The timeline is driven by your gut, not by the calendar. Do not restart just because three days have passed since surgery. If you are still on IV fluids and clear liquids, it is too soon.

Colonoscopy and Other Outpatient Procedures

Colonoscopy prep deserves its own mention because it combines two of the biggest risk factors for SGLT2 inhibitor-related problems: fasting and dehydration. The bowel preparation itself is a powerful laxative that flushes fluid out of your body, and patients are typically on a clear liquid diet for a full day beforehand. Farxiga has a mild diuretic effect on top of that, increasing the chance of significant dehydration. Case reports have linked SGLT2 inhibitors to acute kidney injury during colonoscopy preparation, and the combination of fluid loss and carbohydrate restriction sets the stage for ketoacidosis.⁸

Most gastroenterology practices now recommend holding SGLT2 inhibitors before colonoscopy. The exact timing varies, but a reasonable approach mirrors the surgical guidance: stop three days before the procedure and restart once you are eating normally afterward. If your gastroenterologist has not asked about Farxiga specifically, bring it up. This is a medication many proceduralists outside of endocrinology may not think to ask about.

The Risk of Stopping in Heart Failure Patients

The three-day hold is straightforward for someone who takes Farxiga only for blood sugar control. It gets more complicated when the drug is also keeping heart failure in check. Farxiga has broad effects on how the kidneys handle sodium and fluid, influences that go well beyond glucose.¹¹ Stopping abruptly creates a window where fluid can reaccumulate and cardiac workload increases. Researchers have raised concerns about “rebound” heart failure exacerbations when the drug is withdrawn, and international guidelines do not agree on how to handle this tradeoff.¹²

The SPAQI consensus threads the needle by distinguishing between patients with diabetes alone and those with diabetes plus heart failure or kidney disease. For the latter group undergoing major surgery, the guidance leans toward continuing Farxiga as long as the fasting period is not prolonged. The FDA, EMA (Europe), ANZCA (Australia and New Zealand), and JBDS (UK) all take somewhat different positions on exactly when and for whom to stop. If you have heart failure and are facing surgery, this is a conversation your cardiologist, endocrinologist, and surgical team need to have together. A default “just stop it for three days” decision made by one physician in isolation can cause problems if another physician is managing your heart failure without knowing the drug was held.

International Guideline Differences

If you look up SGLT2 inhibitor surgical guidance from different countries, you will find frustratingly inconsistent advice. The FDA’s approach has historically been conservative, recommending stopping SGLT2 inhibitors at least three days before any scheduled surgery. European and Australian guidelines have been more granular, stratifying by surgery type and indication. The SPAQI 2026 consensus represents the most detailed attempt yet to reconcile these approaches, essentially saying the answer depends on a matrix of factors rather than a single rule.¹²

The inconsistency matters because patients travel, see specialists trained in different systems, and read conflicting information online. If your surgeon says stop three days before and your cardiologist says keep taking it, they may both be following legitimate guidelines from different professional bodies. The right answer requires someone looking at your full picture: what surgery you are having, how long you will fast, what conditions Farxiga is treating, and what your backup plan is for blood sugar or fluid management during the hold period.

Bridging Blood Sugar While Farxiga Is Paused

If Farxiga is your only diabetes medication or a major contributor to your blood sugar control, stopping it three days before surgery creates a glucose management gap. Your blood sugar will likely run higher during those three days and in the immediate postoperative period. For many patients, this is acceptable because short-term hyperglycemia is far less dangerous than ketoacidosis. Your surgical team may adjust other medications temporarily, add a short-acting insulin regimen, or simply monitor closely and accept mildly elevated readings.

What you should not do is try to compensate by dramatically restricting carbohydrates while Farxiga is still in your system during the washout period. The first day or two after stopping, the drug is still partially active. Combining that residual drug effect with carbohydrate restriction is exactly the combination that drives ketone production. Eat normally through the washout period. Save the fasting for the day of surgery when the drug is fully cleared.

What to Tell Your Surgical Team

The most important thing you can do is make sure every member of your perioperative care team knows you take Farxiga. In one case series, only one out of three nonemergent patients who developed euglycemic ketoacidosis had been told to stop their SGLT2 inhibitor before the procedure.⁶ The drug falls into an awareness gap: it is not insulin, it is not a classic oral diabetes pill, and many surgeons and anesthesiologists trained before SGLT2 inhibitors became common may not think to ask about it.

At your preoperative appointment, mention Farxiga by name. Confirm the hold date. Ask whether your team plans to monitor ketone levels or blood gases postoperatively, especially if you are having cardiac surgery or any procedure requiring extended fasting. If you develop nausea, vomiting, abdominal pain, or unusual fatigue in the days after surgery, do not assume it is just part of recovery. Contact your care team and specifically mention that you were recently on an SGLT2 inhibitor, because those symptoms warrant a blood gas check even if your glucose meter reads perfectly fine.